The present invention relates to a method for converting at least one oligo- and/or polysaccharide into fructose comprising the steps of: a) adding to a composition comprising water, phosphate and at least one oligo- and/or polysaccharide at least four enzymes, and b) subsequently enzymatically converting the at least one oligo- and/or polysaccharide to fructose in the presence of the at least four enzymes, wherein in step a) at least one additional saccharide is added, whereby the at least one additional saccharide is selected from the group consisting of saccharides comprising 20 or less monosaccharide residues and/or combinations thereof; wherein in step a) the at least four enzymes, preferably at least five enzymes, are selected from the group consisting of transferases, phosphorylases, mutases, isomerases, hydrolases, phosphatases and combinations thereof; and wherein at least one enzyme in step a) is a phosphatase.

The invention pertains to whey-bound fresh cheese such as cream cheese, and the stabilization thereof using granular starch and an amylomaltase-treated starch and/or an emulsifier, and to methods of making such fresh cheeses. Whey-bound fresh cheeses with these additional ingredients display increased stability, which makes them suitable for application in heated food products. In addition, the invention is directed to food products comprising such whey-bound fresh cheeses, as well to methods of making these food products, and to use of a granular starch and amylomaltase-treated starch for the stabilization of a whey-bound fresh cheese.

The present disclosure relates to a composition for producing tagatose, comprising fructose-6-phosphate-4-epimerase, and a method of producing tagatose using the same.

Disclosed herein are methods of producing hexoses from saccharides by improved enzymatic processes. The improved processes utilize enzymes with higher activities than those previously reported to convert starch or a starch derivative, cellulose or a cellulose derivative, or sucrose to a glucose 6-phosphate (G6P) intermediate.

Provided are a composition for producing tagatose, comprising fructose-6-phosphate 4-epimerase, and a method of producing tagatose using the same.

The present invention relates to a functional C-terminal truncated GDE polypeptide for the treatment of glycogen storage disease III.

Provided are a composition for producing tagatose, comprising fructose-6-phosphate 4-epimerase, and a method of producing tagatose using the same.

This invention provides a range of translatable polynucleotide and oligomer molecules for expressing a human amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL), or a fragment thereof having AGL activity. The polynucleotide and oligomer molecules are expressible to provide the human AGL or a fragment thereof having AGL activity. The molecules can be used as active agents to express an active polypeptide or protein in cells or subjects. The agents can be used in methods for ameliorating, preventing, delaying onset, or treating a disease or condition associated with reduced activity of amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL) in a subject.

The invention relates to immobilized enzyme compositions for the preparation of a hexose. Hexoses include, for example, tagatose, psicose, fructose, allose, mannose, galactose, altrose, talose, sorbose, gulose, idose, and inositol. The invention also relates to an enzymatic process for preparing a hexose from a saccharide by contacting a starch derivative with an immobilized enzyme composition of the invention.

This invention provides a range of translatable polynucleotide and oligomer molecules for expressing a human amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL), or a fragment thereof having AGL activity. The polynucleotide and oligomer molecules are expressible to provide the human AGL or a fragment thereof having AGL activity. The molecules can be used as active agents to express an active polypeptide or protein in cells or subjects. The agents can be used in methods for ameliorating, preventing, delaying onset, or treating a disease or condition associated with reduced activity of amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase (AGL) in a subject.